Baidu
map

CDS 2018:梅斯医学专访杨涛教授:糖尿病分型与诊断

2018-12-02 MedSci MedSci原创

中华医学会糖尿病学分会第二十二次全国学术会议将于11月29日正式开幕,28日下午的会前培训班内容精彩纷呈,来自各地的专家针对基层医生分享了糖尿病诊疗方面的经验。在糖尿病的诊断、分型及综合管理专场上,来自南京医科大学第一附属医院(江苏省人民医院)的杨涛教授分享了糖尿病诊断与分型的相关内容,小编整理如下。

2018年11月28日~12月1日,由中华医学会、中华医学会糖尿病学分会(CDS)主办,江苏省医学会承办的中华医学会糖尿病学分会第二十二次全国学术会议(CDS 2018)在江苏省苏州市盛大召开。


梅斯医学(MedSci)有幸采访到来自南京医科大学第一附属医院(江苏省人民医院)的杨涛教授。



MedSci:杨涛教授,您好!感谢您接受我们的采访,请您简单跟我们分享下,基层医生对糖尿病的诊治现状。

杨涛教授:
糖尿病已经成为健康中国建设必须直面的巨大挑战,基层防治形势更为严峻,基层医生急需持续而有效的培训支持,把糖尿病标准的诊疗技术下沉到县级及以下的医院,使得糖尿病诊治流程标准化和规范化。

MedSci:对糖尿病患者来说,明确的诊断分型十分重要,但除了1型和2型糖尿病,还有很多特殊类型,那么,糖尿病到底分几类?

杨涛教授:在临床实际工作中,医生常常遇到诊断分型不明确的情况。有一种普遍的误解,认为1型糖尿病只会发生在儿童时期,但事实并非如此,1型糖尿病可以发生在任何年龄。对于糖尿病分型,一般按照病因对糖尿病进行分类:1型糖尿病、2型糖尿病、特殊类型糖尿病和妊娠期糖尿病四个类型,同时,需要考虑临床依据、胰岛功能变化的依据。对2型糖尿病来说不再简单的统一,而是要分亚型。对于特殊类型糖尿病,需要更加明确的细分,比如胰岛β细胞功能遗传性缺陷、胰岛素作用遗传性缺陷、胰腺外分泌疾病、内分泌疾病、感染所致,不常见的免疫介导性糖尿病以及其他与糖尿病相关的遗传综合征等等。因此,只有准确的糖尿病分型,才能保证治疗方案的准确性。

MedSci:对于基层医生来说,有没有帮助分型的工具?


杨涛教授:培养一名专业的糖尿病医生需要花10年的时间,如果让全科医生全部成为专科医生非常困难。我们希望通过有效的工具,来辅助基层医生进行分型和诊断。基于1型糖尿病临床诊断模型,我们通过C肽值、BMI值和发病年龄计算出COED-C的数值,然后通过监测可以发现COED-C的变化,从而来指导临床诊断。另外,我们希望通过上下联动的方式,让基层医生接得住病人,进而对病人进行同质化治疗。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1804269, encodeId=85991804269a1, content=<a href='/topic/show?id=be8ce667717' target=_blank style='color:#2F92EE;'>#糖尿病分型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76677, encryptionId=be8ce667717, topicName=糖尿病分型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Jan 03 22:39:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703317, encodeId=c38e1e033170a, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Tue Aug 27 14:39:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277060, encodeId=0a6612e7060d4, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Dec 04 12:39:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377628, encodeId=6bdb13e76280a, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Tue Dec 04 12:39:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042084, encodeId=1b2f104208454, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Dec 03 00:39:00 CST 2018, time=2018-12-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1804269, encodeId=85991804269a1, content=<a href='/topic/show?id=be8ce667717' target=_blank style='color:#2F92EE;'>#糖尿病分型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76677, encryptionId=be8ce667717, topicName=糖尿病分型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Jan 03 22:39:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703317, encodeId=c38e1e033170a, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Tue Aug 27 14:39:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277060, encodeId=0a6612e7060d4, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Dec 04 12:39:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377628, encodeId=6bdb13e76280a, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Tue Dec 04 12:39:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042084, encodeId=1b2f104208454, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Dec 03 00:39:00 CST 2018, time=2018-12-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1804269, encodeId=85991804269a1, content=<a href='/topic/show?id=be8ce667717' target=_blank style='color:#2F92EE;'>#糖尿病分型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76677, encryptionId=be8ce667717, topicName=糖尿病分型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Jan 03 22:39:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703317, encodeId=c38e1e033170a, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Tue Aug 27 14:39:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277060, encodeId=0a6612e7060d4, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Dec 04 12:39:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377628, encodeId=6bdb13e76280a, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Tue Dec 04 12:39:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042084, encodeId=1b2f104208454, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Dec 03 00:39:00 CST 2018, time=2018-12-03, status=1, ipAttribution=)]
    2018-12-04 一闲
  4. [GetPortalCommentsPageByObjectIdResponse(id=1804269, encodeId=85991804269a1, content=<a href='/topic/show?id=be8ce667717' target=_blank style='color:#2F92EE;'>#糖尿病分型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76677, encryptionId=be8ce667717, topicName=糖尿病分型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Jan 03 22:39:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703317, encodeId=c38e1e033170a, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Tue Aug 27 14:39:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277060, encodeId=0a6612e7060d4, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Dec 04 12:39:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377628, encodeId=6bdb13e76280a, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Tue Dec 04 12:39:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042084, encodeId=1b2f104208454, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Dec 03 00:39:00 CST 2018, time=2018-12-03, status=1, ipAttribution=)]
    2018-12-04 yangpeizhi
  5. [GetPortalCommentsPageByObjectIdResponse(id=1804269, encodeId=85991804269a1, content=<a href='/topic/show?id=be8ce667717' target=_blank style='color:#2F92EE;'>#糖尿病分型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76677, encryptionId=be8ce667717, topicName=糖尿病分型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Jan 03 22:39:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703317, encodeId=c38e1e033170a, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Tue Aug 27 14:39:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277060, encodeId=0a6612e7060d4, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Dec 04 12:39:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377628, encodeId=6bdb13e76280a, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Tue Dec 04 12:39:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042084, encodeId=1b2f104208454, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Dec 03 00:39:00 CST 2018, time=2018-12-03, status=1, ipAttribution=)]
    2018-12-03 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

Diabetes Care:股骨头缺血性坏死与糖尿病之间的关系

由此可见,糖尿病患者发生股骨头缺血性坏死的风险增加1.16倍。

CDS2018:金标准也须与时俱进:看CGM如何超越HbA1c,助力血糖全面管理

2018年11月30日,在中华医学会糖尿病学分会第二十二次全国学术会议(CDS2018)上,上海交通大学附属第六人民医院包玉倩教授从血糖管理指标方面分析了持续葡萄糖监测(CGM)相较于糖化血红蛋白(HbA1c)用于血糖控制与评估的优势,为广大参会者更深入了解CGM提供了重要信息。

CDS2018:白蛋白尿的重新认识:另一种心肾风险因素?老外专家带您了解一下

糖尿病患者更容易患上肾脏并发症,目前对于糖尿病肾病管理的意识越来越强烈。越来越多的研究打破了原来对白蛋白尿的认识,对于糖尿病肾病管理起到一定的启示作用。

CDS2018:糖尿病肾脏病诊治的新靶点——肾小管上皮细胞

糖尿病所致的肾损害并不仅仅局限于肾小球,肾小管上皮细胞在糖尿病肾脏病(DKD)的早期和进展期均发挥了关键作用。2018年11月30日,在中华医学会糖尿病学分会第二十二次全国学术会议(CDS2018)上,南方医科大学南方医院薛耀明教授从DKD防治的严峻形势入手,介绍了肾小管上皮细胞在DKD发病中的重要性以及肾小管上皮细胞作为DKD治疗新靶点的最新研究进展。

CDS2018:吸粉无数的卡格列净,到底有何过人之处?

随着循证医学证据的积累,糖尿病治疗已经历了从单纯控制高血糖到多因素管理的转变。但是,糖尿病合并心血管疾病(CVD)及肾脏疾病的防控形势依然十分严峻。在中华医学会糖尿病学分会第二十二次全国学术会议(CDS2018)上,由中国人民解放军总医院母义明教授担任主席,中山大学孙逸仙纪念医院李焱教授和天津医科大学代谢病医院陈莉明教授担任讲者,分别从新型降糖药SGLT2抑制剂卡格列净的机制、循证出发,对2型糖尿

CDS2018:孙子林:基于同伴支持和移动医疗的院外糖尿病管理模式

2018年11月29日,在中华医学会糖尿病学分会第二十二次全国学术会议(CDS2018)的糖尿病健康管理专题中,东南大学附属中大医院孙子林教授就基于同伴支持和移动医疗的院外糖尿病管理模式发表了学术报告。

Baidu
map
Baidu
map
Baidu
map